| Dr Charles William Britt Jr, MD | |
|
2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 | |
| (208) 625-4000 | |
| Not Available |
| Full Name | Dr Charles William Britt Jr |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 2003 Kootenai Health Way, Coeur D Alene, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154497279 | NPI | - | NPPES |
| 0151194 | Other | L & I | |
| 1114099 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | MD00036265 (Washington) | Primary |
| Entity Name | Kootenai Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235288655 PECOS PAC ID: 4789641598 Enrollment ID: O20041214000230 |
News Archive
Clinical studies show that new drugs that target malignant cells of HER2-positive breast cancer, such as Pertuzumab and Trastuzumab Emtansine (T-DM1), increase life expectancy in patients with advanced breast cancer.
K-V Pharmaceutical Company announced today it has been informed by Hologic, Inc. that site initiation and patient enrollment has begun at international clinical trial sites in Europe in the ongoing trial of Gestiva™ (hydroxyprogesterone caproate injection, 250 mg/1 mL), commonly referred to as "17P," for the prevention of preterm birth in women pregnant with a single baby with a history of singleton spontaneous preterm birth.
A new therapy for type 1 diabetes? A promising treatment for deadly viruses? Does a common treatment for children with severe infection actually cause more harm than good? These are important questions being investigated by pediatric researchers at Mattel Children's Hospital UCLA.
Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
Biological markers responsible for extreme exhaustion in patients with cancer have now been linked to fatigue in those with Parkinson's disease, according to new research from Rice University.
› Verified 8 days ago
| Entity Name | Kootenai Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174661151 PECOS PAC ID: 1355792276 Enrollment ID: O20240111003252 |
News Archive
Clinical studies show that new drugs that target malignant cells of HER2-positive breast cancer, such as Pertuzumab and Trastuzumab Emtansine (T-DM1), increase life expectancy in patients with advanced breast cancer.
K-V Pharmaceutical Company announced today it has been informed by Hologic, Inc. that site initiation and patient enrollment has begun at international clinical trial sites in Europe in the ongoing trial of Gestiva™ (hydroxyprogesterone caproate injection, 250 mg/1 mL), commonly referred to as "17P," for the prevention of preterm birth in women pregnant with a single baby with a history of singleton spontaneous preterm birth.
A new therapy for type 1 diabetes? A promising treatment for deadly viruses? Does a common treatment for children with severe infection actually cause more harm than good? These are important questions being investigated by pediatric researchers at Mattel Children's Hospital UCLA.
Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
Biological markers responsible for extreme exhaustion in patients with cancer have now been linked to fatigue in those with Parkinson's disease, according to new research from Rice University.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles William Britt Jr, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-4000 | Dr Charles William Britt Jr, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-4000 |
News Archive
Clinical studies show that new drugs that target malignant cells of HER2-positive breast cancer, such as Pertuzumab and Trastuzumab Emtansine (T-DM1), increase life expectancy in patients with advanced breast cancer.
K-V Pharmaceutical Company announced today it has been informed by Hologic, Inc. that site initiation and patient enrollment has begun at international clinical trial sites in Europe in the ongoing trial of Gestiva™ (hydroxyprogesterone caproate injection, 250 mg/1 mL), commonly referred to as "17P," for the prevention of preterm birth in women pregnant with a single baby with a history of singleton spontaneous preterm birth.
A new therapy for type 1 diabetes? A promising treatment for deadly viruses? Does a common treatment for children with severe infection actually cause more harm than good? These are important questions being investigated by pediatric researchers at Mattel Children's Hospital UCLA.
Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
Biological markers responsible for extreme exhaustion in patients with cancer have now been linked to fatigue in those with Parkinson's disease, according to new research from Rice University.
› Verified 8 days ago
Dr. Christin J Mcintyre, MD, PHD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1250 W Ironwood Dr Ste 303, Coeur D Alene, ID 83814 Phone: 503-276-1295 Fax: 234-444-5496 | |
John Michael Thurston, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 250 Northwest Blvd Ste 200, Coeur D Alene, ID 83814 Phone: 208-225-8642 Fax: 208-795-8079 | |
Dr. James Y. Lea, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2022 N Government Way, Coeur D Alene, ID 83814 Phone: 208-667-5536 Fax: 208-765-1194 | |
Dr. Michah Brasseur, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-4000 Fax: 208-625-5101 | |
Lizl Maureen Lasky, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 158, Coeur D Alene, ID 83814 Phone: 208-625-5100 Fax: 208-625-5101 | |
Cynthia Murphy, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 158, Coeur D Alene, ID 83814 Phone: 208-625-5100 Fax: 208-625-5101 |